DISCLAIMER

Every effort has been made to ensure the accuracy of this text, and that the best information available has been used. However, palliativedrugs.com Ltd neither represents nor guarantees that the practices described herein will, if followed, ensure safe and effective patient care. The recommendations contained in this book reflect the editors’ judgement regarding the state of general knowledge and practice in the field as of the date of publication. Information in a book of this type can never be all-inclusive, and therefore will not cover every eventuality.

Thus, those who use this book must make their own determinations regarding specific safe and appropriate patient-care practices, taking into account the personnel, equipment, and practices available at the hospital or other facility at which they are located. Neither palliativedrugs.com Ltd nor the editors can be held responsible for any liability incurred as a consequence of the use or application of any of the contents of this book. Mention of specific product brands does not imply endorsement.

Particularly when prescribing a drug for the first time, a doctor (or other independent prescriber) should study the contents of the manufacturer’s Summary of Product Characteristics (SPC), paying particular attention to indications, contra-indications, cautions, drug interactions, and undesirable effects.
EDITORIAL STAFF

Editors-in-Chief
Robert Twycross DM, FRCP
Emeritus Clinical Reader in Palliative Medicine, Oxford University

Andrew Wilcock DM, FRCP
Macmillan Clinical Reader in Palliative Medicine and Medical Oncology, Nottingham University
Consultant Physician, Hayward House, Nottingham University Hospitals NHS Trust, City Campus

Paul Howard BMedSci, MRCP
Consultant in Palliative Medicine, Earl Mountbatten House, Isle of Wight NHS Trust

Senior Editor
Sarah Charlesworth BPharm, DipClinPharm, MRPharmS
Specialist Pharmacist, Palliative Care Information and Website Management, Hayward House, Nottingham University Hospitals NHS Trust, City Campus

Editor
Claire Stark Toller MA, MA, MRCP
Locum Consultant in Palliative Medicine, Macmillan Unit, Royal Bournemouth and Christchurch Hospitals NHS Trust

Associate Editor
Julie Mortimer BPharm, MRPharmS
Malcolm Mortimer Media, Nottingham (former Senior Editor)

Editorial Board
Andrew Broadbent BMedSc, MHM, FRACP, FChPM
Hammondcare Director of Palliative Care, Northern Sydney, Head of Palliative Care Royal North Shore Hospital, Senior Lecturer University of Sydney, NSW, Australia

Rachel Burman MA, FRCP
Consultant in Palliative Care, King’s College Hospital NHS Foundation Trust, Cicely Saunders Institute, London, UK

Venkata Chaitanya MRCP
Consultant in Palliative Medicine, Derby Hospitals NHS Trust, Derby, UK

Alpna Chauhan MRCP
Consultant in Palliative Medicine, John Eastwood Hospice, Sutton-in-Ashfield, Nottinghamshire, UK

Brian Creedon MMedSci, MRCPi
Consultant in Palliative Medicine, Waterford Regional Hospital, Waterford, Ireland

Vincent Crosby FRCP
Consultant in Palliative Medicine, Hayward House Specialist Palliative Care Unit, Nottingham University Hospitals NHS Trust, Nottingham, UK
Andrew Davies  MSc, MD, FRCP
Consultant in Palliative Medicine, St. Luke’s Cancer Centre, Royal Surrey County Hospital, Guildford, UK

Joanne Droney, PhD, MRCPI
Consultant in Palliative Medicine, Royal Marsden Hospital, London, UK

Jo Elverson MA(Ed) MRCP
Consultant in Palliative Medicine, Helen and Douglas House Hospices for Children & Young Adults, Oxford, UK

Ruth England MRCP
Consultant in Palliative Medicine, Derby Hospitals NHS Trust, Derby, UK

Marie Fallon MD, FRCP
St Columbas Hospice Chair of Palliative Medicine, University of Edinburgh and Edinburgh Cancer Centre, UK.

Jeff Fry BSc, PhD
Associate Professor and Reader in Molecular Toxicology, School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, UK

Catherine Gwilt BSc, MRCP
Specialist Registrar in Palliative Medicine, KSS Palliative Medicine rotation, London, UK

Vanessa Halliday PhD, RD
Lecturer in Public Health, School of Health and Related Research, University of Sheffield, UK

Janet Hardy BSc, MD, FRACP
Director, Department of Palliative and Supportive Care, Mater Health Services, Brisbane; Professor of Palliative Medicine, University of Queensland, Australia

Miriam Johnson MD, FRCP, MRCP
Professor of Palliative Medicine, Hull York Medical School, University of Hull, Hull, UK

Paul Keeley FRCP
Consultant in Palliative Medicine, Glasgow Royal Infirmary, Glasgow, Scotland, UK

Vaughan Keeley PhD, FRCP
Consultant in Palliative Medicine, Derby Hospitals NHS Trust, Derby, UK

Samuel King MRCP
Palliative Medicine Consultant, St Elizabeth Hospice and Ipswich Hospital Trust, Ipswich, Suffolk, UK

Malgorzata Krajnik MD, PhD
Head of Palliative Care Department, Nicolaus Copernicus University, L Rydygier Collegium Medicum, Bydgoszcz, Poland; Consultant in Palliative Medicine, University Hospital No 1, Bydgoszcz, Poland

Susie Lapwood MA, MRCGP, DFSRH, DipPallMed
Head of Research, Education and Professional Development and Senior Specialty Doctor, Helen and Douglas House Hospices for Children and Young Adults, Oxford UK

Mark Lee MD, MRCP
Consultant in Palliative Care, St Benedict’s Hospice and Specialist Palliative Care Centre, Sunderland, UK

Vivian Lucas MA, MRCGP, DA, DRCOG
Medical Director, Garden House Hospice, Letchworth Garden City, UK

Michael Lucey MB, BMedSci, FRCPi
Consultant in Palliative Medicine, Milford Hospice, Limerick and HSE mid West, Ireland
Staffan Lundstrom MD, PhD
Department of Palliative Medicine, Stockholms Sjukhem Foundation and Karolinska Institute, Stockholm, Sweden

Tim Morgan BSc, FRCP, FRCS
Macmillan Consultant and Lead Physician in Palliative Medicine, Roxburghe House and Aberdeen Royal Infirmary, NHS Grampian and Honorary Senior Lecturer, Aberdeen University, UK

Simon Noble MD, FRCP, Dip Pall Med
Clinical Reader in Palliative Medicine, Cardiff University, UK

Victor Pace FRCP, FRCS, DipPallMed
Consultant in Palliative Medicine, St Christopher’s Hospice, London, UK

Rachel Quibell MRCGP, FRCP
Consultant in Palliative Medicine, Newcastle upon Tyne Hospitals FT and Marie Curie Hospice, Newcastle, UK

Joy Ross PhD, MRCP
Consultant in Palliative Medicine, Royal Marsden Hospital, London, UK

John Shaw PhD
Hayward House Study Centre, Nottingham University Hospitals NHS Trust, City Campus, Nottingham, UK

Anna Spathis MA, MSc, MRCGP, FHEA
Consultant in Palliative Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

Mark Taubert MRCGP, MSc, DipPallMed
Consultant in Palliative Medicine, Holme Tower Marie Curie Centre, Penarth, UK

Jillian Wall MRCP
Registrar in Palliative medicine, Hayward House Specialist Palliative Care Unit, Nottingham University Hospitals NHS Trust, Nottingham, UK

Rebecca White BSc, MSc, MRPharmS (IPresc), FFRPS
Consultant Pharmacist: Nutrition & Intestinal Failure, Oxford University Hospitals NHS Trust, Oxford, UK

Zbigniew Zylicz MD, PhD
Consultant in Palliative Medicine, Hildegard Hospiz, Basel, Switzerland
CONTENTS

Preface xi
Summary of main changes in PCF5 xii
How PCF is constructed xiii
Getting the most out of PCF xv
The use of drugs beyond (off-label) and without marketing authorization xix
Drug names xxv
Abbreviations xxvii

Part 1 Drug Monographs

1 Gastro-intestinal system 1
   Antacids 1
   Antimuscarinics 5
   Prokinetics 22
   H₂-receptor antagonists 26
   Misoprostol 29
   Proton pump inhibitors 31
   Loperamide 37
   Laxatives 40
   Products for haemorrhoids 59
   Pancreatin 60

2 Cardiovascular system 63
   Furosemide 63
   Spironolactone 68
   Systemic local anaesthetics 71
   Clonidine 76
   Glyceryl trinitrate 79
   Nifedipine 83
   Anticoagulants 86
   Haemostatics 98

3 Respiratory system 105
   Bronchodilators 105
   Inhaled corticosteroids 125
   Oxygen 129
   Drugs for cough 138
## 4 Central nervous system

<table>
<thead>
<tr>
<th>Subtopic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psychotropics</td>
<td>147</td>
</tr>
<tr>
<td>Benzodiazepines</td>
<td>148</td>
</tr>
<tr>
<td>Melatonin</td>
<td>165</td>
</tr>
<tr>
<td>Antipsychotics</td>
<td>168</td>
</tr>
<tr>
<td>Antidepressants</td>
<td>190</td>
</tr>
<tr>
<td>*Psychostimulants</td>
<td>224</td>
</tr>
<tr>
<td>*Cannabinoids</td>
<td>229</td>
</tr>
<tr>
<td>Anti-emetics</td>
<td>235</td>
</tr>
<tr>
<td>Anti-epileptics</td>
<td>254</td>
</tr>
</tbody>
</table>

## 5 Analgesics

<table>
<thead>
<tr>
<th>Subtopic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Principles of use of analgesics</td>
<td>291</td>
</tr>
<tr>
<td>Adjuvant analgesics</td>
<td>295</td>
</tr>
<tr>
<td>Paracetamol</td>
<td>299</td>
</tr>
<tr>
<td>Nefopam</td>
<td>305</td>
</tr>
<tr>
<td>Non-steroidal anti-inflammatory drugs (NSAIDs)</td>
<td>307</td>
</tr>
<tr>
<td>Weak opioids</td>
<td>346</td>
</tr>
<tr>
<td>Strong opioids</td>
<td>357</td>
</tr>
<tr>
<td>Opioid antagonists</td>
<td>450</td>
</tr>
</tbody>
</table>

## 6 Infections

<table>
<thead>
<tr>
<th>Subtopic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibacterials in palliative care</td>
<td>461</td>
</tr>
<tr>
<td>Oropharyngeal candidosis</td>
<td>465</td>
</tr>
<tr>
<td>Metronidazole</td>
<td>468</td>
</tr>
<tr>
<td>Urinary tract infections</td>
<td>471</td>
</tr>
<tr>
<td>Cellulitis in a lymphoedematous limb</td>
<td>476</td>
</tr>
<tr>
<td>Clostridium difficile infection</td>
<td>482</td>
</tr>
<tr>
<td>Helicobacter pylori gastritis</td>
<td>486</td>
</tr>
</tbody>
</table>

## 7 Endocrine system and immunomodulation

<table>
<thead>
<tr>
<th>Subtopic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bisphosphonates</td>
<td>489</td>
</tr>
<tr>
<td>Systemic corticosteroids</td>
<td>499</td>
</tr>
<tr>
<td>Demeclocycline</td>
<td>510</td>
</tr>
<tr>
<td>Desmopressin</td>
<td>514</td>
</tr>
<tr>
<td>Drugs for diabetes mellitus</td>
<td>518</td>
</tr>
<tr>
<td>*Octreotide</td>
<td>530</td>
</tr>
<tr>
<td>Progestogens</td>
<td>536</td>
</tr>
<tr>
<td>Danazol</td>
<td>540</td>
</tr>
<tr>
<td>*Thalidomide</td>
<td>543</td>
</tr>
</tbody>
</table>

## 8 Urinary tract disorders

<table>
<thead>
<tr>
<th>Subtopic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tamsulosin</td>
<td>549</td>
</tr>
<tr>
<td>Oxybutynin</td>
<td>551</td>
</tr>
<tr>
<td>Methenamine hippurate</td>
<td>554</td>
</tr>
</tbody>
</table>
CONTENTS

Cranberry juice 555
Catheter patency solutions 557
Discoloured urine 559

9 Nutrition and blood 561
Anaemia 561
Ascorbic acid (vitamin C) 564
Phytomenadione (vitamin K₁) 566
Potassium 568
Magnesium 571
Zinc 577

10 Musculoskeletal and joint diseases 583
Depot corticosteroid injections 583
Rubefacients and other topical products 584
Skeletal muscle relaxants 589

11 Ear, nose and oropharynx 599
Mouthwashes 599
Artificial saliva 601
Pilocarpine 602
Drugs for oral inflammation and ulceration 604
Cerumenolytics 608

12 Skin 611
Emollients 611
Topical antipruritics 618
Barrier products 622

13 Anaesthesia 625
*Ketamine 625
*Propofol 634

Part 2 General Topics
14 Guidance about prescribing in palliative care 639
15 Opioid dose conversion ratios 661
16 Drug treatment in the imminently dying 669
17 Pre-emptive prescribing in the community 681
18 Management of postoperative pain in opioid-dependent patients 687
19 Analgesic drugs and fitness to drive 691
20 Continuous subcutaneous drug infusions 697
21 Spinal analgesia 713
22 Drug administration to patients with swallowing difficulties or enteral feeding tubes 725
23 Nebulized drugs 753
24 Prolongation of the QT interval in palliative care 759
CONTENTS

25 Variability in response to drugs 767
26 Drug-induced movement disorders 781
27 Anaphylaxis 787
28 Drugs for pruritus 793
29 Oral nutritional supplements 801

Appendices
A1 Obtaining unauthorized (unlicensed) products 817
A2 Taking controlled and prescription drugs to other countries 819
A3 Compatibility charts 821

Indexes
Generic drugs 839
Supplementary topics 845
Welcome to the latest edition of the *Palliative Care Formulary (PCF)*, written primarily for the UK. Regional adaptations include German and Japanese editions (see [www.palliativedrugs.com](http://www.palliativedrugs.com) for details).

The target audience comprises doctors, nurses and pharmacists involved in the care of patients receiving palliative/hospice care. *PCF* is a core textbook for medical registrars in Palliative Medicine in the UK. It is used in some areas to fulfil the NHS National Cancer Standards requirement for specialist palliative care services within a Cancer Centre and Network to have a core palliative care drug formulary and is referred to in many official healthcare documents, e.g. NICE CKS guidelines.

Although written primarily with cancer patients in mind, *PCF* contains specific material relating to a number of other life-limiting diseases, e.g. COPD, congestive heart failure, renal failure, and Parkinson's disease. *PCF* also includes a number of *Quick Clinical Guides* and *Quick Prescribing Guides* (listed inside the back cover and in the Supplementary topic index). To enhance user-friendliness, each *Guide* is limited to no more than two pages, and references are not normally included. We welcome feedback on these. We also encourage the donation of clinical guidance from other sources for posting on our website (e-mail copies to hq@palliativedrugs.com).

The production of a book of this nature depends partly on the help and advice of numerous colleagues, both past and present. We acknowledge with gratitude the support of clinical colleagues, and members of the palliativedrugs.com community who have provided feedback, particularly via surveys or by contributing to the *Syringe Driver Survey Database*.

We acknowledge with thanks the advice provided by various correspondents, including: Victoria Barnett, Claudia Bausewein, James Beattie, Christopher Blick, Ronald Elin, Bethany Foster, Philippa Hawley, Sue Hollingsworth, Aleksandra Kotlinska–Lemieszek, Louise Lynch, Mary Mihalyo, Eva Murphy, Renee Page, Russell Portenoy, Constanze Remi, Jan Rémi, John Shuster, Nigel Sykes, and by Medical Information Departments in the pharmaceutical industry.

We are grateful to Sarah Keeling for co-ordinating production, John Shaw for assistance in copy-editing, and to Karen Isaac for secretarial support.

Robert Twycross
Andrew Wilcock
Paul Howard
*Editors-in-chief*
*July 2014*
SUMMARY OF MAIN CHANGES IN PCF5

Since the publication of PCF4 in 2011, every drug monograph has been reviewed and updated. With the anticipated demise of Symptom Management in Advanced Cancer, several items have been transferred into the Formulary:

- Chapter 2 in Haemostatics: a section about Haematuria, including a Table of bladder instillations and irrigations for haemorrhagic cystitis
- Chapter 10 in Skeletal muscle relaxants: a list of drugs which can cause cramps, and a Box detailing the use of anti-epileptics for treating cramp
- Chapter 11 in Drugs for oral inflammation and ulceration: a list of drugs which can cause oral ulceration.

New Chapters
25 Variability in response to drugs (replaces Cytochrome P450)
28 Drugs for pruritus

Deleted monographs
Dextropropoxyphene has been withdrawn in the UK, Europe, the USA, and other countries because of its relatively common use in intentional overdose and its potential fatal toxicity in accidental overdose. Accordingly, the monograph in earlier editions of PCF is now redundant, and has been removed.

Other monographs have been subsumed into generic drug class monographs, e.g.:
- Dalteparin and Enoxaparin (→ LMWH)
- Flecainide (→ Systemic local anaesthetics)
- Methylphenidate and Modafinil (→ Psychostimulants)
- Naloxone and Naltrexone (→ Opioid antagonists)

Monographs
Either new or amalgamations:
- Anticoagulants
- Low molecular weight heparin (LMWH)
- Haemostatics
- Gabapentin and pregabalin
- Psychostimulants
- Cannabinoids
- Opioid antagonists
- Bisphosphonates

Quick Practice Guides
These have been renamed as either Quick Clinical Guides (e.g. Heparin-Induced Thrombocytopenia) or Quick Prescribing Guides (e.g. Depression, Opioid-induced constipation). For full list, see inside the back cover.
HOW PCF IS CONSTRUCTED

There is continual review and updating of the contents of PCF over a three year cycle. These updates are published regularly on-line, with the whole book published in print every three years.

The Palliative Care Formulary (PCF) is a unique independent professional publication which provides essential information for prescribers and health professionals involved in palliative and hospice care. PCF contains authoritative independent guidance on best practice, and helps to ensure that drugs are used appropriately, safely, and optimally.

Recommended International Non-proprietary Names (rINN) are used for drugs. The order of drug monographs broadly follows that of the British National Formulary (BNF).

Editorial team
The PCF editorial team is co-ordinated by three medically qualified Editors-in-chief who are (or have been) accredited specialists in Palliative Medicine and a specialist palliative care pharmacist. For each print edition, every section of PCF is reviewed and updated with the help of an Editorial Board. Suggestions for new monographs are discussed by the PCF editorial team, and experts identified to assist in the preparation of new documents.

The Editorial Board
The Editorial Board mainly comprises palliative care physicians appointed on the basis of their clinical knowledge and expertise. Editorial Board members have committed to reviewing one or more drug monographs or chapters, and work in liaison with the editorial team. Responsibilities include scrutinizing literature databases such as PubMed, and accessing and studying relevant new publications.

Correspondents
Correspondents are drawn from a range of medical specialties. They include doctors, pharmacists, nurses, and others who provide advice on the text by:
  - checking amendments for scientific accuracy, and to enhance clarity
  - providing additional expert opinion in areas of controversy or when reliable evidence is lacking
  - advising on areas when the PCF diverges from a manufacturer’s Summary of Product Characteristics (SPC)
  - providing additional validation and clinical evidence about unauthorized (off-label) use.

Sources of PCF information
PCF uses various sources for its information, including:

Summary of product characteristics (SPC)
The SPCs are the principal source of product information and are carefully reviewed to ensure that PCF monographs are fully up-to-date in this respect.

Literature
Research papers and reviews relating to the drugs featured in PCF are carefully processed. When a difference between the advice in the PCF and a paper is noted, the new information is evaluated for reliability and relevance to UK clinical practice. If necessary, new text is drafted and thoroughly reviewed by the editorial team with support, as needed, from the Editorial Board and/or Correspondents.

PCF also has access to many on-line information resources (see p.xviii). For example, www.azcert.org is used to flag drugs which have the potential to prolong QT interval to a
clinically relevant degree, and www.psychotropical.com is used to help adjudicate whether a report about serotonin toxicity is reliable.

**Systematic reviews**

*PCF* monitors various databases of systematic reviews, including the *Cochrane Library* and several other web-based resources. Reviews published in *Clinical Evidence* are used to validate *PCF* advice.

**Consensus guidelines**

The advice in *PCF* is checked against consensus guidelines produced by expert bodies including the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), and the Scottish Intercollegiate Guidelines Network (SIGN).

*PCF* also takes note of other expert bodies which produce clinical guidelines relevant to palliative care, e.g. Association for Palliative Medicine, British Lymphology Society.

**Statutory information**

*PCF* routinely processes relevant information from various Government bodies, including Statutory Instruments and regulations affecting the Prescription only Medicines Order, Controlled Drugs and from the Medicines and Healthcare products Regulatory Agency (MHRA). Safety warnings issued by the Commission on Human Medicines (CHM) and guidelines on drug use issued by the UK health departments are routinely processed.

Relevant professional statements issued by the Royal Pharmaceutical Society (RPS), Nursing and Midwifery Council (NMC) and General Medical Council (GMC) are included in *PCF* as are guidelines from the medical Royal Colleges.

**Pricing information**

Drug prices are net prices based on those in the online edition of the *BNF* at the time of the monograph update. For products not included in the *BNF*, prices are checked directly with suppliers. However, particularly in hospitals, heavily discounted contract prices radically alter both the absolute and relative acquisition costs.

Prices worked out for 28 days’ supply are generally based on the most convenient strength for the patient and cheapest pack size. Costs for broken bulk, dispensing/sourcing fees and delivery charges are not included. Costs under £5 have been rounded up to the next 50p; prices over £5 are rounded up to the next full pound.

**Comments from industry**

Manufacturers are contacted directly if there are queries about the content of an SPC.
Information in a book of this type can never be all-inclusive, and thus will not cover every eventuality. Readers should satisfy themselves as to the appropriateness of the information before applying it in practice.

Particularly when prescribing a drug for the first time, a doctor (or other independent prescriber) should study the contents of the manufacturer’s Summary of Product Characteristics (SPC), paying particular attention to indications, contra-indications, cautions, drug interactions, and undesirable effects (also see p.xvii).

PCF often refers to the use of drugs beyond the scope of their marketing authorization (product licence). The use of drugs in this way clearly has implications for the prescriber (see p.xix).

A cautious approach is always necessary when prescribing for the frail, the elderly, and patients with hepatic impairment, renal impairment or respiratory insufficiency (see Chapter 14, p.639). Further, if caring for a woman who is pregnant or breast-feeding, or for someone with porphyria, it is crucial to double-check a drug’s suitability in both the BNF and its SPC.

The literature on the pharmacology of pain and symptom management in end-stage disease is growing continually, and it is impossible for anyone to be familiar with all of it. This is where a book like PCF comes into its own as a major accessible resource for prescribing clinicians involved in palliative care.

PCF is not an easy read, indeed it was never intended that it would be read from cover to cover. It is essentially a reference book – to study the monograph of an individual drug, or class of drugs, with specific questions in mind.

In Part 1, the sections generally follow the systematic order of the British National Formulary (BNF). Drugs marked with an asterisk (*) should generally be used only by, or after consultation with, a specialist palliative care service.

Part 2 and the appendices deal with themes that transcend the drug monographs, e.g. pre-emptive prescribing in the community, continuous subcutaneous infusions, administering drugs via enteral tubes, the use of nebulized drugs.

Reliable knowledge, levels of evidence and strength of recommendations

Research is the pursuit of reliable knowledge. The gold standard for drug treatment is the randomized controlled trial (RCT) or, better, a systematic review of homogeneous RCTs.

Over the last 20–30 years, numerous systems have been published for categorizing levels of evidence and the strength of the derived recommendations. Box A reproduces the system used by the British Medical Journal. This checklist is based on material published by three main sources, namely the US Agency for Health Care Policy and Research, the NHS Management Executive, and the North of England Guidelines Group.1–3

However, it is important to recognize that the RCT is not the only source of reliable knowledge. Broadly speaking, sources of knowledge can be conveniently grouped under three headings:

- instrumental, includes RCT data and data from other high-quality studies
- interactive, refers to anecdotal data (shared clinical experience), including retrospective and prospective surveys
- critical, data unique to the individual in question (e.g. personal choice) and societal/cultural factors (e.g. financial and logistic considerations).5

Relying on one type of knowledge alone is not good practice. All three sources must be exploited in the process of therapeutic decision-making.
Pharmaceutical company information
Although the manufacturer’s SPC is an important source of information about a drug, it is important to remember that many published studies are sponsored by the drug company in question. This can lead to a conflict of interest between the desire for objective data and the need to make one’s own drug as attractive as possible. It is thus best to treat information from company representatives as inevitably biased. The information provided by PCF is commercially independent, and should serve as a counterbalance to manufacturer bias.

Remember: it is often safer to stick with an ‘old favourite’, and not seek to be among the first to prescribe a newly released product – which may simply be a ‘me-too’ drug rather than true innovation.

Generic drugs
PCF encourages generic prescribing. Apart from occasional exceptions, e.g. m/r formulations of diltiazem, nifedipine, theophylline and some anti-epileptics, there is little reliable evidence that different preparations of the same drug are significantly different in terms of bio-availability and efficacy. However, particularly for oral morphine preparations, the Department of Health (London) recommends including the brand name of opioid analgesics on the prescription and dispensing label, to avoid unwittingly switching brands and confusing the patient.

Indications
PCF often refers to the use of drugs beyond the scope of their marketing authorization (product licence). The use of drugs in this way clearly has implications for the prescriber (see p.xix). As always, readers should satisfy themselves as to the appropriateness of the information before applying it in practice.

In PCF generally, only those indications which are relevant to palliative care are listed, with unauthorized indications or uses preceded by a † sign. However, a succinct summary is not always

---

### Box A A scheme for categorizing evidence and grading recommendations

<table>
<thead>
<tr>
<th>Category</th>
<th>Level of evidence</th>
<th>Grade</th>
<th>Strength of recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ia</td>
<td>Evidence obtained from a meta-analysis of RCTs</td>
<td>A</td>
<td>Directly based on Category I evidence without extrapolation</td>
</tr>
<tr>
<td>Ib</td>
<td>Evidence from at least one RCT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IIa</td>
<td>Evidence obtained from at least one well-designed controlled study without randomization</td>
<td>B</td>
<td>Directly based on Category II evidence or by extrapolation from Category I evidence</td>
</tr>
<tr>
<td>IIb</td>
<td>Evidence obtained from at least one other well-designed quasi-experimental study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>Evidence obtained from well-designed non-experimental descriptive studies, such as comparative studies, correlation studies and case studies</td>
<td>C</td>
<td>Directly based on Category III evidence or by extrapolation from Category I or II evidence</td>
</tr>
<tr>
<td>IV</td>
<td>Evidence obtained from expert committee reports or opinions and/or clinical experiences of respected authorities</td>
<td>D</td>
<td>Directly based on category IV evidence or by extrapolation from Category I, II, or III evidence. This grading indicates that directly applicable clinical studies of good quality are absent or not readily available</td>
</tr>
</tbody>
</table>

---

GETTING THE MOST OUT OF PCF

---

xvi www.palliativedrugs.com
possible because the Marketing Authorization reflects what the manufacturer applied for. Thus, authorized indications can vary between drugs within a therapeutic class or for the same drug by different:

- manufacturers
- routes of administration, e.g. haloperidol tablets and injection
- formulations, e.g. buprenorphine TD patches, desmopressin tablets
- pack sizes, e.g. buprenorphine tablets.

We have endeavoured to indicate such circumstances with the statement: ‘Authorized indications vary between products; consult SPC for details’. In any event, before using a product for the first time, the SPC should be studied.

**Contra-indications and cautions**

Contra-indications and cautions listed in SPCs sometimes vary between different manufacturers of the same drug. Thus, a contra-indication in one SPC may be styled a caution in another, and vice versa.

In PCF, we do not include universal contra-indications (e.g. history of hypersensitivity to the drug), and have generally not included a contra-indication from the SPC if the use of the drug in the stated circumstance is accepted prescribing practice in palliative care.

Advice regarding dosing a drug in renal impairment can vary. When this occurs, PCF favours the opinion of the independent Renal Drug Handbook over the manufacturer’s SPC.

However, as always, a cautious approach is necessary when prescribing for the frail, the elderly, and patients with organ impairment or respiratory insufficiency (see Chapter 14, p.639). If caring for a woman who is pregnant or breast-feeding, or for someone with porphyria, it is crucial to check a drug’s suitability in both the BNF and SPC.

**Pharmacokinetics**

Generally, pharmacokinetic data are taken from Martindale: the complete drug reference or from a manufacturer’s SPC. Other sources are referenced in the text.

**Drug interactions**

Generally, information on drug interactions is taken from Stockley’s drug interactions or from a manufacturer’s SPC. Other sources are referenced in the text.

It is assumed that clinicians are aware of the risk of commonsense pharmacodynamic interactions, e.g. that the concurrent prescription of two or more drugs with sedative properties is likely to result in more sedation than if each drug was prescribed alone. On the other hand, pharmacokinetic interactions (leading to either increased or reduced effect) are generally covered in individual drug monographs and in Chapter 25, p.767.

**Undesirable effects of drugs**

As recommended by the European Commission, the term ‘undesirable effect’ is used rather than ‘side effect’ or ‘adverse drug reaction’. Wherever possible, undesirable effects are categorized as:

- very common (>10%)
- common (<10%, >1%)
- uncommon (<1%, >0.1%)
- rare (<0.1%, >0.01%)
- very rare (<0.01%).

PCF generally includes information on the very common and common undesirable effects. Selected other undesirable effects are also included, e.g. uncommon or rare ones which may have serious consequences. The manufacturer’s SPC should be consulted for a full list of undesirable effects.
Supply
The list of products in the Supply section is not exhaustive. Generally, generic products and selected proprietary ones are included, e.g. an alternative proprietary formulation not available as a generic.

Literature references
In choosing references, articles in hospice and palliative care journals have frequently been selected preferentially. Such journals are likely to be more readily available to our readers, and often contain detailed discussion.

It is not feasible to reference every statement in PCF. However, readers are invited to enter into constructive dialogue with the Editors via the Bulletin Board on www.palliativedrugs.com. This is currently accessed by > 25,000 health professionals worldwide.

Online sources of information
Website references are not routinely given for articles available in traditionally published journals. However, various full-text core journals are available free to UK NHS staff with an Athens password through the NHS Evidence Services website at https://www.evidence.nhs.uk.

Information from the BNF and BNFc is freely available, after registration, from www.bnf.org.uk for users in the UK and the HiNARI group of developing countries. References to manufacturer’s SPCs and PILs are generally not included. However, most can be freely accessed from www.medicines.org.uk or obtained directly from the manufacturer.

Online sources of information are referenced when this is the usual route of publication and access is freely available, e.g. UK Department of Health guidelines, MHRA Drug Safety Updates, NICE guidance, SIGN guidance. The website address quoted is for the homepage or the page from which the guidance can be found and downloaded.

Whenever possible, subscription websites have been avoided. However, to ensure that the most current information is included when revising PCF, the following standard reference texts are consulted from subscribed access to Medicines Complete (www.medicinescomplete.com):

- American Hospital Formulary Service (AHFS)
- Handbook of drug administration via enteral feeding tubes
- Handbook on injectable drugs
- Martindale: the complete drug reference
- Stockley’s drug interactions.

These are available in all UK Medicines Information Services.

THE USE OF DRUGS BEYOND (OFF-LABEL) AND WITHOUT MARKETING AUTHORIZATION

The use of drugs for off-label purposes is widespread. Surveys suggest that up to one quarter of all prescriptions in palliative care come into this category.\textsuperscript{1,2} In PCF, the symbol † is used to indicate such use. However, it is impractical to highlight all cases of off-label use, particularly when it is simply a matter of the route or dose being different from those in the manufacturer’s Summary of Product Characteristics (SPC).

It is important for prescribers to understand that marketing authorization for drugs regulates the marketing activities of pharmaceutical companies, and not the prescriber’s clinical practice. Even so, off-label use does have implications for prescribers, and these are discussed in this section.

Definitions

Marketing authorization
Marketing authorization (MA) means that a drug has been approved by a regulatory body for use in humans and authorized for specific indications, and can be marketed by the relevant pharmaceutical company.

Off-label use
Off-label describes the use of a drug beyond the specifications of its MA, e.g. for an unauthorized indication, or in doses, preparations, patient population or route not covered by the MA.

Unauthorized drug
There is no simple definition of an unauthorized drug. Essentially it is a drug which does not have MA for medicinal use in humans. Unauthorized drugs include:

- the final product when two or more drugs are mixed together for administration e.g. in a syringe for CSCI (see below and Chapter 20, p.697)
- ‘specials’ obtained from a commercial company with a ‘specials’ manufacturing licence, e.g. alfentanil solution for nasal/buccal administration (see Alfentanil, p.385)
- preparations made in a local pharmacy at the request of a prescriber for an individual named patient
- drugs that have had a MA withdrawn but special provision has been made by the MHRA for a continued supply, e.g. co-proxamol or for which MA has been abandoned, suspended or revoked, e.g. cisapride, oxetacaine, thioridazine
- drugs that are authorized in another country but not in the UK and are imported into the UK by a specialist importing company, e.g. hydromorphone injection
- new drugs undergoing clinical trials or awaiting a MA, e.g. if a patient wishes to continue an investigational product after a clinical trial.

The authorization (licensing) process
Before a drug can be marketed in the UK, it requires MA (previously product licence). There are four application procedures in the European Union:

- centralized, application evaluated by the European Medicines Agency (EMEA); the European Commission grants a single MA valid for the whole European Union
- decentralized, simultaneous application made by several member states, with one taking the lead; if successful, national MA then being granted in each state
• mutual recognition, application for authorization in a member state when MA exists in another member state; the new member state relies on the original member state’s evaluation as a basis for its decision

• national, application for MA in only one member state; in the UK the application is evaluated by the Medicines and Healthcare products Regulatory Agency (MHRA) on behalf of the Licensing Authority, a body consisting of UK health ministers.3 Certain drugs, e.g. for HIV/AIDS, cancer, neurodegenerative diseases, must be authorized through the centralized procedure. The UK Parallel Import Licensing Scheme also allows a drug authorized in other European Union states to be imported and marketed in the UK, if it has labels and a Patient Information Leaflet (PIL) in English.

In the UK, the MHRA evaluation comprises an evaluation of the efficacy, safety and quality of the drug from a medical, pharmaceutical and scientific viewpoint to ensure that it satisfies predefined criteria. Advice is sought from the Commission on Human Medicines (CHM), an independent advisory body, which in turn is assisted by specialist expert advisory groups.

At a European level, the Committee for Medicinal Products for Human Use (CHMP) fulfils a similar role to the CHM. New drugs will have relatively limited safety information and the pharmaceutical company is generally required to outline a risk management plan.

Restrictions are imposed if evidence of safety and efficacy is unavailable in particular patient groups, e.g. children. MA is granted for up to 5 years and then renewed following re-evaluation of the risks and benefits.3 Thus, the process ensures that in relation to the drug’s authorized uses, there has been due consideration of its efficacy, safety and quality, that the benefits outweigh the potential risks, and that there is appropriate accompanying product information and labelling.4 The MA defines the conditions and patient groups for which a pharmaceutical company can market and supply the drug, with more information about the drug’s authorized uses provided by the manufacturer in the Summary of Product Characteristics (SPC).

However, the MA does not limit what the drug could be used for (i.e. off-label use), and clinical experience may reveal other indications. For these to receive a MA, additional evidence would need to be gathered and submitted. The considerable expense of this, perhaps coupled with a small market for a new indication, often means that a revised application is not made.

Prescribing for off-label indications or unauthorized drugs

In the UK, the following may legally prescribe authorized drugs for off-label indications and unauthorized drugs:5–7

• doctors, specifically safeguarded in the UK Medicines Act 1968

• nurses, pharmacists, podiatrists, physiotherapists and radiographers who are registered as supplementary prescribers, provided it is done within the framework of an agreed Clinical Management Plan for a specific patient in partnership with a doctor or dentist

• nurses or pharmacists who are registered as independent prescribers if this is accepted clinical practice and within their clinical competence.

These prescriptions can be dispensed by pharmacists8 and administered by nurses or midwives.9 In addition to clinical trials, such prescriptions may be justified:

• when prescribing generic formulations for which indications are not described

• with established drugs for proven but unauthorized indications

• with drugs for conditions for which there are no other treatments (even in the absence of strong evidence)

• when using drugs in individuals not covered by the MA, e.g. children

• when mixing drugs before administration, e.g. two or more drugs in a syringe for administration by continuous infusion.10,11

Any independent prescriber, including non-medical prescribers, can mix drugs and direct others to mix, as can supplementary prescribers when the preparation is part of the Clinical Management Plan for an individual patient. Legislation on mixing now extends to controlled drugs. Existing good practice recommendations should be followed in relation to mixing all drugs.10 Preparations resulting from mixing drugs, other than when one product is a vehicle for the administration of the other, cannot be supplied or administered under Patient Group Direction arrangements.

The responsibility for the consequences of prescribing a drug under such circumstances lies with the prescriber, who must be competent, operate within the professional codes and ethics of their statutory bodies and the prescribing practices of their employers.4–6 The prescriber must be...
<table>
<thead>
<tr>
<th>Status</th>
<th>The drug</th>
<th>Published data</th>
<th>The illness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Most reasonable</td>
<td>Authorized for the intended indication</td>
<td>Well known; generally safe</td>
<td>Life-threatening</td>
</tr>
<tr>
<td></td>
<td>Authorized for another indication; other related products authorized for the intended indication</td>
<td>Well known; some clear undesirable effects</td>
<td></td>
</tr>
<tr>
<td></td>
<td>An authorized product; not authorized for the intended indication, nor are similar medicines</td>
<td>Well known; has serious undesirable effects or</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Little studied; no clear undesirable effects</td>
<td></td>
</tr>
<tr>
<td>Least reasonable</td>
<td>Drug/product not authorized at all</td>
<td>Not studied</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>No published data available</td>
<td>Trivial</td>
</tr>
</tbody>
</table>

**Figure 1**  Factors influencing the reasonableness of prescribing decisions.
fully informed about the actions and uses of the drug, be assured of the quality of the particular product, and in the light of published evidence, balance both the potential good and the potential harm which might ensue.

It is possible to draw a hierarchy of degrees of reasonableness relating to off-label and unauthorized drug use (Figure 1). The more dangerous the medicine and the more flimsy the evidence the more difficult it is to justify its prescription.

The PIL will not contain information about unauthorized indications. Thus, it is important that prescribers (or those authorizing treatment on their behalf) provide sufficient information to patients about the drug’s expected benefits and potential risks (undesirable effects, drug interactions, etc.) to enable them to make an informed decision (Box A). The GMC also recommends that when prescribing a drug off-label, doctors should:

- be satisfied that such use would better serve the patient's needs than an authorized alternative (if one exists)
- be satisfied that there is sufficient evidence/experience of using the drug to show its safety and efficacy, seeking the necessary information from appropriate sources
- record in the patient’s clinical notes the drug prescribed and, when not following common practice, the reasons for the choice
- take responsibility for prescribing the drug and for overseeing the patient's care, including monitoring the effects of the drug, or arrange for another suitable doctor to do so.12

Non-medical prescribers should ensure that they are familiar with their own profession's prescribing standards, e.g. NMC. Although the advice is broadly similar to that of the GMC, there are some differences.13,14

In palliative care, off-label drug use is so widespread that concerns have been expressed that a detailed explanation on every occasion is impractical, would be burdensome for the patient and increase anxiety, and could result in the refusal of beneficial treatment.15 A UK survey of over 220 palliative medicine doctors showed that, when using a drug for a routine off-label indication, <5% always mention this to their patients, and 20% never do. However, in situations where there is little evidence and limited clinical experience to support a drug’s off-label use, these figures change to 75% and 5% respectively.16

This is a grey area and each clinician must decide how explicit to be; an appropriate level of counselling and a sensitive approach is essential. Some NHS Trusts and other institutions have policies in place and have produced information cards or leaflets for patients and caregivers (Box B). A joint position statement has also been produced by the British Pain Society and the Association for Palliative Medicine (Box C),17 together with a patient information booklet.18

![Box A](https://www.palliativedrugs.com)

**Box A** Providing information for patients about the use of drugs beyond and without marketing authorization

Patients (or their proxy) should be given sufficient information about any proposed drug treatment to allow them to make an informed decision. Questions must be answered fully and honestly.

Some drugs are routinely used beyond their licence, e.g. when treating children and in palliative care.

In emergencies, or when there is no realistic alternative treatment and such information is likely to cause distress, it may not be practical or necessary to draw attention to the licence.

In other situations, when the prescription of an unauthorized drug is supported by authoritative clinical guidance, it may be sufficient to describe in general terms why the drug is not authorized for the proposed use.

When prescribing a drug which is unauthorized or off-label in a non-routine way, or when suitable authorized alternatives exist, the reason for this should be explained to the patient.
Use of medicines beyond their licence (off-label)

This leaflet contains important information about your medicines, so please read it carefully. Generally, medicines prescribed by your doctor or bought over-the-counter from a pharmacist are licensed for use by the Medicines and Healthcare products Regulatory Agency (MHRA).

The licence (or marketing authorization) specifies the conditions and patient groups for which the medicine should be used, and how it should be given.

Patient Information Leaflets (PILs) supplied with medicines reflect the licensed uses. When a medicine is used beyond its licence, the information in the PIL may not be relevant to your circumstances.

In palliative care, medicines are commonly used for conditions or in ways that are not specified on the licence.

Your doctor will use medicines beyond the licence only when there is research and experience to back up such use.

Medicines used very successfully beyond the licence include some antidepressants and anti-epileptics (anti-seizure drugs) when given to relieve some types of pain. Also, instead of injecting into a vein or muscle, medicines are often given subcutaneously (under the skin) because this is more comfortable and convenient.

If you would like more information, please ask your doctor or pharmacist.

Alternatively, contact:

Dr/Nurse ........................................................................................................................................................

Hospital ........................................................................................................................................................

........................................................................................................................................................................

........................................................................................................................................................................

Tel ...................................................................................................................................................................
**Box C** Recommendations of the Association for Palliative Medicine of Great Britain and Ireland and the British Pain Society\(^ {17}\)

**Use of medicines beyond (off-label) and without (unlicensed) Marketing Authorization (MA) in palliative care and pain medicine**

1. This statement should be seen as reflecting the views of a responsible body of opinion within the clinical specialties of palliative medicine and pain medicine.

2. The use of medicines beyond and without a MA in palliative care and pain medicine practice is both necessary and common and should be seen as a legitimate aspect of clinical practice.

3. Organizations providing palliative care and pain medicine services should support therapeutic practices that are underpinned by evidence and advocated by a responsible body of professional opinion.

4. Health professionals involved in prescribing medicines beyond or without MA should select those medicines that offer the best balance of benefit against harm for any given patient.

5. Choice of treatment requires partnership between patients and health professionals, and informed consent should be obtained, whenever possible, before prescribing any medicine.

6. Patients should be offered accurate, clear and specific information that meets their needs about the use of medicines beyond or without a MA in accordance with professional regulatory body guidance. The information needs of carers and other health professionals involved in the care of the patient should also be considered and met as appropriate. The use of information cards or leaflets may help with this. It is often unnecessary to take additional steps when recommending medicines beyond or without MA.

7. Health professionals should inform, change and monitor their practice with regard to medicines beyond or without MA in the light of evidence from audit and published research.

8. The Department of Health should work with health professionals and the pharmaceutical industry to enable and encourage the extension of product licences where there is evidence of benefit in circumstances of defined clinical need.
DRUG NAMES

All drugs marketed in Europe are now known by their recommended International Nonproprietary (generic) Name (rINN). In the past, most publications in the UK used the now outdated British Approved Name (BAN). To aid understanding of the older literature, significant differences between BANs and rINNs are listed in Table 1. However, when the difference is simply, e.g. ‘f’ instead of ‘ph’, ‘e’ instead of ‘oe’, or ‘t’ instead of ‘th’, these generally have not been included.

In the USA, United States Adopted Names (USANs) take precedence over rINNs. USANs are also included in Table 1 where these differ significantly from rINNs.

Note: in the UK, the BANs adrenaline and noradrenaline are still used in conjunction with the corresponding rINNs, i.e. adrenaline (epinephrine) and noradrenaline (norepinephrine).

Care should be taken with proprietary drug names in different countries. Some proprietary names are similar in spelling or pronunciation but contain different drugs. Further, some products with identical proprietary names contain different drugs, e.g. Urex® in the USA contains methenamine but, in Australia, furosemide.

Table 1 Drug names relevant to palliative care for which the rINN, BAN and/or USAN differ

<table>
<thead>
<tr>
<th>rINN</th>
<th>BAN</th>
<th>USAN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alimemazine</td>
<td>Trimeprazine</td>
<td>Trimeprazine</td>
</tr>
<tr>
<td>Amobarbital</td>
<td>Amylbarbitone</td>
<td>Bendroflumethiazide</td>
</tr>
<tr>
<td>Bendroflumethiazide</td>
<td>Bendrofluazide</td>
<td>Penicillin G</td>
</tr>
<tr>
<td>Bendroflumethiazide</td>
<td>Bendrofluazide</td>
<td>Calcitonin</td>
</tr>
<tr>
<td>Benzylpenicillin</td>
<td>calcitonin</td>
<td>Carboxymethylcellulose</td>
</tr>
<tr>
<td>Calcitonin (salmon)</td>
<td>Salcatonin</td>
<td>Chlorpheniramine</td>
</tr>
<tr>
<td>Carmellose</td>
<td>Chlormethiazole</td>
<td>Chlorpheniramine</td>
</tr>
<tr>
<td>Chlorphenamine</td>
<td>Chlorpheniramine</td>
<td>Chlorpheniramine</td>
</tr>
<tr>
<td>Clomethiazole</td>
<td>Chlormethiazole</td>
<td>Chlorpheniramine</td>
</tr>
<tr>
<td>Dexamfetamine</td>
<td>Dexamphetamine</td>
<td>Dextroamphetamine</td>
</tr>
<tr>
<td>Dextropropoxyphene</td>
<td>Dicyclomine</td>
<td>Propoxyphene</td>
</tr>
<tr>
<td>Dicycloverine</td>
<td>Dicyclomine</td>
<td>Dicyclomine</td>
</tr>
<tr>
<td>Diethylstilbestrol</td>
<td>Stilboestrol</td>
<td>Diethylstilbestrol</td>
</tr>
<tr>
<td>Dosulepin</td>
<td>Dothiepin</td>
<td>Dothiepin</td>
</tr>
<tr>
<td>Epinephrine</td>
<td>Adrenaline</td>
<td>Epinephrine</td>
</tr>
<tr>
<td>Glibenclamide</td>
<td>Glycerine</td>
<td>Glyburide</td>
</tr>
<tr>
<td>Glyceryl trinitrate</td>
<td>Ispaghula</td>
<td>Glycerin</td>
</tr>
<tr>
<td>Hyoscine</td>
<td>Levothyroxine</td>
<td>Nitroglycerin</td>
</tr>
<tr>
<td>Isoprenaline</td>
<td>Levomepromazine</td>
<td>Scopolamine</td>
</tr>
<tr>
<td>Levomethamphetamine</td>
<td>Methotrapeazine</td>
<td>Isoproterenol</td>
</tr>
<tr>
<td>Levotyroxine</td>
<td>Thyroine</td>
<td>Psyllium</td>
</tr>
<tr>
<td>Liquid paraffin</td>
<td>Mineral oil</td>
<td></td>
</tr>
<tr>
<td>Methenamine hippurate</td>
<td>Hexamine hippurate</td>
<td></td>
</tr>
<tr>
<td>Paracetamol</td>
<td>Acetaminophen</td>
<td></td>
</tr>
<tr>
<td>Pethidine</td>
<td>Meperidine</td>
<td></td>
</tr>
</tbody>
</table>

continued
Table 1  Continued

<table>
<thead>
<tr>
<th>rINN</th>
<th>BAN</th>
<th>USAN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phenobarbital</td>
<td>Phenobarbitone</td>
<td>Penicillin V</td>
</tr>
<tr>
<td>Phenoxyacetylpenicillin</td>
<td>Penicillin V</td>
<td></td>
</tr>
<tr>
<td>Phytomenadione</td>
<td>Phytomadione</td>
<td>Penicillin V</td>
</tr>
<tr>
<td>Retinol</td>
<td>vitamin A</td>
<td>vitamin A</td>
</tr>
<tr>
<td>Rifampicin</td>
<td>Rifampin</td>
<td>vitamin A</td>
</tr>
<tr>
<td>Salbutamol</td>
<td>Albuterol</td>
<td>vitamin A</td>
</tr>
<tr>
<td>Simeticone(^a)</td>
<td>Simeticone</td>
<td>Simeticone</td>
</tr>
<tr>
<td>Sodium cromoglicate</td>
<td>Sodium cromoglycate</td>
<td>Cromolyn sodium</td>
</tr>
<tr>
<td>Tetracaine</td>
<td>Amethocaine</td>
<td></td>
</tr>
<tr>
<td>Trihexyphenidyl</td>
<td>Benzhexol</td>
<td>Trihexyphenidyl</td>
</tr>
</tbody>
</table>

\(^a\) silica-activated dimeticone; known in some countries as activated dimethylpolysiloxane.

1 FDA (2006) Consumers filling U.S. prescriptions abroad may get the wrong active ingredient because of confusing drug names. 
ABBREVIATIONS

Drug administration

In 2005, the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) in the USA published National Patient Safety Goals. These include a series of recommendations about ways in which confusion (and thus errors) can be reduced by avoiding the use of certain abbreviations on prescriptions. The full set of recommendations is available at http://www.jointcommission.org/standards_information/npsgs.aspx.

Although some traditional abbreviations remain acceptable (e.g. Table 1), other commonly used ones are not. Thus, it is now recommended that the following are written in full:

- at bedtime
- once daily
- each morning
- every other day.

These four recommendations have also been adopted in PCF.

Although the following conventions have not been adopted in PCF, readers should be aware of the following recommendations for handwritten and printed prescriptions, and other printed medical matter, e.g. packaging, patient records:

- include a space between the drug dose and the unit of measure, e.g. 25 mg, not 25mg
- write ‘per’ instead of an oblique (mistaken for a figure 1), e.g. 200 mg per day, not 200mg/day
- use ‘subcut’ or ‘subcutaneous’ instead of SC (mistaken for SL)
- write ‘less than’ or ‘greater than’ instead of < and > (mistaken for a letter L or figure 7; or written the wrong way round and thus signifying the opposite of the intended meaning).

Further, although it has been recommended in the UK that ‘PR’ (prolonged-release) should become the generic term for ‘slow-release’, ‘extended-release’ etc., PR is a time-honoured abbreviation for ‘per rectum’. It is in this latter sense that PR will be used in PCF. As in earlier editions, ‘m/r’ (modified-release) will be used.

Note: in earlier editions, ‘normal-release’ was used for non-modified products. However, because of international popular usage, in this edition the term ‘immediate-release’ is used (without abbreviation).

Table 1  Abbreviations used in PCF for the times of drug administration

<table>
<thead>
<tr>
<th>Times</th>
<th>UK</th>
<th>Latin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Twice per day</td>
<td>b.d.</td>
<td>bis die</td>
</tr>
<tr>
<td>Three times per day</td>
<td>t.d.s.</td>
<td>ter die sumendus</td>
</tr>
<tr>
<td>Four times per day</td>
<td>q.d.s.</td>
<td>quarta die sumendus</td>
</tr>
<tr>
<td>Every 4 hours etc.</td>
<td>q4h</td>
<td>quaque quarta hora</td>
</tr>
<tr>
<td>Rescue medication (as needed/required)</td>
<td>p.r.n.</td>
<td>pro re nata</td>
</tr>
<tr>
<td>Give immediately</td>
<td>stat</td>
<td></td>
</tr>
</tbody>
</table>

a.c.  ante cibum (before food)
amp  ampoule containing a single dose (cf. vial)
CD  preparation subject to prescription requirements under the Misuse of Drugs Act (UK); for regulations see BNF
CIVI  continuous intravenous infusion
### Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CSCI</td>
<td>Continuous subcutaneous infusion</td>
</tr>
<tr>
<td>e/c</td>
<td>Enteric-coated (gastroresistant)</td>
</tr>
<tr>
<td>ED</td>
<td>Epidural</td>
</tr>
<tr>
<td>IM</td>
<td>Intramuscular</td>
</tr>
<tr>
<td>IT</td>
<td>Intrathecal</td>
</tr>
<tr>
<td>IV</td>
<td>Intravenous</td>
</tr>
<tr>
<td>IVI</td>
<td>Intravenous infusion</td>
</tr>
<tr>
<td>m/r</td>
<td>Modified-release; alternatives, controlled-release, extended-release, prolonged-release, slow-release, sustained-release</td>
</tr>
<tr>
<td>NHS</td>
<td>Not prescribable on NHS prescriptions</td>
</tr>
<tr>
<td>OTC</td>
<td>Over-the-counter (i.e. can be obtained without a prescription)</td>
</tr>
<tr>
<td>p.c.</td>
<td>Post cibum (after food)</td>
</tr>
<tr>
<td>PO</td>
<td>Per os, by mouth</td>
</tr>
<tr>
<td>POM</td>
<td>Prescription-only medicine</td>
</tr>
<tr>
<td>PR</td>
<td>Per rectum</td>
</tr>
<tr>
<td>PV</td>
<td>Per vaginam</td>
</tr>
<tr>
<td>SC</td>
<td>Subcutaneous</td>
</tr>
<tr>
<td>SL</td>
<td>Sublingual</td>
</tr>
<tr>
<td>TD</td>
<td>Transdermal</td>
</tr>
<tr>
<td>TM</td>
<td>Transmucosal</td>
</tr>
<tr>
<td>vial</td>
<td>Sterile container with a rubber bung containing either a single or multiple doses (cf. amp)</td>
</tr>
<tr>
<td>WFI</td>
<td>Water for injections</td>
</tr>
</tbody>
</table>

### General

* specialist use only
† unlicensed use
ACBS Advisory Committee on Borderline Substances
AHFS American Hospital Formulary Service
BNF British National Formulary
BP British Pharmacopoeia
CHM Commission on Human Medicines
CSM Committee on Safety of Medicines (now part of CHM)
DH Department of Health (UK)
EMEA European Medicines Agency
EORTC European Organisation for Research and Treatment of Cancer
FDA Food and Drug Administration (USA)
IASP International Association for the Study of Pain
IDIS International Drug Information Service
MCA Medicines Control Agency (now MHRA)
MHRA Medicines and Healthcare products Regulatory Agency (formerly MCA)
NICE National Institute for Health and Care Excellence
NPF Nurse Prescribers’ Formulary
NPSA National Patient Safety Association
NYHA New York Heart Association
PCS/PCU Palliative care service/unit
PEG Percutaneous endoscopic gastrostomy
PIL Patient Information Leaflet (UK)
rINN Recommended International Non-proprietary Name
RPS Royal Pharmaceutical Society
SIGN Scottish Intercollegiate Guidelines Network
SPC Summary of Product Characteristics (UK)
UK United Kingdom
UKMI UK Medicines Information
USA United States of America
USP United States Pharmacopoeia
VAS Visual analogue scale, 0–100mm
WHO World Health Organization
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACE</td>
<td>angiotensin-converting enzyme</td>
</tr>
<tr>
<td>ADH</td>
<td>antidiuretic hormone (vasopressin)</td>
</tr>
<tr>
<td>ATP</td>
<td>adenosine triphosphate</td>
</tr>
<tr>
<td>AUC</td>
<td>area under the plasma concentration-time curve</td>
</tr>
<tr>
<td>β₂</td>
<td>beta 2 adrenergic (receptor)</td>
</tr>
<tr>
<td>CHF</td>
<td>congestive heart failure</td>
</tr>
<tr>
<td>C&lt;sub&gt;max&lt;/sub&gt;</td>
<td>maximum plasma drug concentration</td>
</tr>
<tr>
<td>CNS</td>
<td>central nervous system</td>
</tr>
<tr>
<td>COX</td>
<td>cyclo-oxygenase; alternative, prostaglandin synthase</td>
</tr>
<tr>
<td>COPD</td>
<td>chronic obstructive pulmonary disease</td>
</tr>
<tr>
<td>CKD</td>
<td>chronic kidney disease</td>
</tr>
<tr>
<td>CRP</td>
<td>C-reactive protein</td>
</tr>
<tr>
<td>CSF</td>
<td>cerebrospinal fluid</td>
</tr>
<tr>
<td>CT</td>
<td>computed tomography</td>
</tr>
<tr>
<td>D&lt;sub&gt;2&lt;/sub&gt;</td>
<td>dopamine type 2 (receptor)</td>
</tr>
<tr>
<td>DIC</td>
<td>disseminated intravascular coagulation</td>
</tr>
<tr>
<td>DVT</td>
<td>deep vein thrombosis</td>
</tr>
<tr>
<td>ECG (EKG)</td>
<td>electrocardiogram</td>
</tr>
<tr>
<td>EFT</td>
<td>enteral feeding tube</td>
</tr>
<tr>
<td>ERCP</td>
<td>endoscopic retrograde cholangiopancreatography</td>
</tr>
<tr>
<td>FBC</td>
<td>full blood count</td>
</tr>
<tr>
<td>FEV&lt;sub&gt;1&lt;/sub&gt;</td>
<td>forced expiratory volume in 1 second</td>
</tr>
<tr>
<td>FRC</td>
<td>functional residual capacity</td>
</tr>
<tr>
<td>FSH</td>
<td>follicle-stimulating hormone</td>
</tr>
<tr>
<td>FVC</td>
<td>forced vital capacity of lungs</td>
</tr>
<tr>
<td>GABA</td>
<td>gamma-aminobutyric acid</td>
</tr>
<tr>
<td>Gi</td>
<td>gastro-intestinal</td>
</tr>
<tr>
<td>Hb</td>
<td>haemoglobin</td>
</tr>
<tr>
<td>HIV</td>
<td>human immunodeficiency virus</td>
</tr>
<tr>
<td>H&lt;sub&gt;1&lt;/sub&gt;, H&lt;sub&gt;2&lt;/sub&gt;</td>
<td>histamine type 1, type 2 (receptor)</td>
</tr>
<tr>
<td>Ig</td>
<td>immunoglobulin</td>
</tr>
<tr>
<td>INR</td>
<td>international normalized ratio</td>
</tr>
<tr>
<td>κ</td>
<td>kappa-opioid (receptor)</td>
</tr>
<tr>
<td>LABA</td>
<td>long-acting β₂-adrenergic receptor agonist</td>
</tr>
<tr>
<td>LFTs</td>
<td>liver function tests</td>
</tr>
<tr>
<td>LH</td>
<td>luteinizing hormone</td>
</tr>
<tr>
<td>LMWH</td>
<td>low molecular weight heparin</td>
</tr>
<tr>
<td>MAOI</td>
<td>mono-amine oxidase inhibitor</td>
</tr>
<tr>
<td>MARI</td>
<td>mono-amine re-uptake inhibitor</td>
</tr>
<tr>
<td>MRI</td>
<td>magnetic resonance imaging</td>
</tr>
<tr>
<td>MSU</td>
<td>mid-stream specimen of urine</td>
</tr>
<tr>
<td>μ</td>
<td>mu-opioid (receptor)</td>
</tr>
<tr>
<td>NaSSA</td>
<td>noradrenergic and specific serotoninergic antidepressant</td>
</tr>
<tr>
<td>NDRI</td>
<td>noradrenaline (norepinephrine) and dopamine re-uptake inhibitor</td>
</tr>
<tr>
<td>NG</td>
<td>nasogastric</td>
</tr>
<tr>
<td>NJ</td>
<td>nasojejunal</td>
</tr>
<tr>
<td>NMDA</td>
<td>N-methyl D-aspartate</td>
</tr>
<tr>
<td>NNH</td>
<td>number needed to harm, i.e. the number of patients needed to be treated in order to harm one patient sufficiently to cause withdrawal from a drug trial</td>
</tr>
<tr>
<td>NNT</td>
<td>number needed to treat, i.e. the number of patients needed to be treated in order to achieve 50% improvement in one patient compared with placebo</td>
</tr>
<tr>
<td>NO</td>
<td>nitric oxide</td>
</tr>
<tr>
<td>NRI</td>
<td>noradrenaline (norepinephrine) re-uptake inhibitor</td>
</tr>
<tr>
<td>NSAID</td>
<td>non-steroidal anti-inflammatory drug</td>
</tr>
<tr>
<td>PaCO&lt;sub&gt;2&lt;/sub&gt;</td>
<td>arterial partial pressure of carbon dioxide</td>
</tr>
<tr>
<td>PaO&lt;sub&gt;2&lt;/sub&gt;</td>
<td>arterial partial pressure of oxygen</td>
</tr>
</tbody>
</table>
ABBREVIATIONS

PCA patient-controlled analgesia
PE pulmonary embolus/embolism
PEF peak expiratory flow
PG prostaglandin
PPI proton pump inhibitor
RCT randomized controlled trial
RIMA reversible inhibitor of mono-amine oxidase type A
RTI respiratory tract infection
SaO2 oxygen saturation
SNRI serotonin and noradrenaline (norepinephrine) re-uptake inhibitor
SRE skeletal-related events
SSRI selective serotonin re-uptake inhibitor
TCA tricyclic antidepressant
TIBC total iron-binding capacity; alternative, plasma transferrin concentration
TlCO transfer factor of the lung for carbon monoxide
Tmax time to reach Cmax
UTI urinary tract infection
VEGF vascular endothelial growth factor
VIP vaso-active intestinal polypeptide
WBC white blood cell
w/v weight of solute (g) per 100mL

Units

cm centimetre(s)
cps cycles per sec
dL decilitre(s)
g gram(s)
Gy Gray(s), a measure of radiation
h hour(s)
Hg mercury
kcal kilocalories
kg kilogram(s)
L litre(s)
mg milligram(s)
microL microlitre(s)
micromol micromole(s)
mm millimetre(s)
mmol millimole(s)
min minute(s)
mosmol milli-osmole(s)
msec millisecond
nm nanometre(s)
nmol nanomole(s); alternative, nM
sec second(s)